Advance the development of SCY-247, a novel antifungal currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula
Award Notice Posted
- Solicitation number
- BAA-23-100-SOL-00004
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Awarded
- to Scynexis Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75A50126C00007 Federal contract award
- NAICS code
- Not on record
- PSC
- Not on record
- Place of performance
- Jersey City, New Jersey 07302, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded contract 75A50126C00007 to Scynexis, Inc. for $213,943,726 on September 25, 2026, to advance development of SCY-247, a novel antifungal in Phase 1 clinical trials for treatment of invasive candidiasis and prophylaxis of invasive fungal disease in oral and intravenous formulations.
The award was made under no set-aside.
Notice text
Awarded contract 75A50126C00007 to Scynexis, Inc. for 213943726.00 on 2026-09-25.
Notice history
5 of 13 notices listed here. See the rest on GovTribe.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity